A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of BIIB021 Administered Once or Twice Daily to Subjects With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2015
At a glance
- Drugs CNF 2024 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Biogen
- 06 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Dec 2010 Planned end date changed from 1 Sep 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 12 May 2010 Planned end date changed from 1 Mar 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.